title: Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection.
abstract: BACKGROUND
  Although many combination therapies have been proposed, there is still interest in identifying simple, inexpensive, effective protocols that have high rates of success.
  
  
  OBJECTIVE
  To investigate the role of the new soluble form of bismuth, ranitidine bismuth citrate, in twice-a-day therapy for Helicobacter pylori infection.
  
  
  METHODS
  Patients with histologically and culture proven H. pylori infection received ranitidine bismuth citrate 400 mg, tetracycline HCl 500 mg, and clarithromycin 500 mg, each b.d. for 14 days, followed by 300 mg ranitidine once a day for 4 additional weeks. Outcome was assessed 4 or more weeks after the end of antimicrobial therapy by repeat endoscopy with histology and culture (49 patients) or urea breath testing (14 patients).
  
  
  RESULTS
  Sixty-three patients completed the therapy, 59 men and four women (average age 56.7 years; range 31-75 years). All patients had clarithromycin-susceptible strains prior to therapy. H. pylori infection was cured in 94% (95% CI: 85-98%). There was a therapy failure in one patient who took the medicine for only 1 day and stopped because of side-effects. Three of the isolates from treatment failures were available post-failure; two were clarithromycin-resistant and one was susceptible. Side-effects were severe in two patients (3%) and moderate in three (primarily diarrhoea).
  
  
  CONCLUSIONS
  Twice-a-day ranitidine bismuth citrate, tetracycline, clarithromycin triple therapy was well tolerated and effective for the treatment of H. pylori infection in patients with clarithromycin-susceptible H. pylori.
authors: Department of Medicine, Veterans Affairs Medical Center and Baylor College of Medicine, Houston, TX, USA. dgraham@bcm.tmc.edu
authors: D Y
authors: DY
authors: Graham
authors: J
authors: J
authors: Hoffman
authors: S Y
authors: SY
authors: Anderson
authors: W
authors: W
authors: Qureshi
authors: M S
authors: MS
authors: Osato
authors: H M
authors: HM
authors: El-Zimaity
mesh_terms: D000328:Adult; D000368:Aged; D001729:Bismuth / Q000008:administration & dosage*; D017291:Clarithromycin / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011899:Ranitidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D013752:Tetracycline / Q000008:administration & dosage*
chemical_list: C073340:ranitidine bismuth citrate; D011899:Ranitidine; D013752:Tetracycline; D017291:Clarithromycin; D001729:Bismuth